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Abstract
Photodynamic antimicrobial chemotherapy (PACT) is a novel alternative antimicrobial therapy that elicits a broad mechanism 
of action and therefore has a low probability of generating resistance. Such properties make PACT ideally suited for utilization 
in localized applications such as burn wounds. The aim of this study was to determine the antimicrobial activity of MB and 
temoporfin against both a S. aureus isolate and a P. aeruginosa isolate in light (640 nm) and dark conditions at a range of time 
points (0–20 min). A Staphylococcus aureus isolate and a Pseudomonas aeruginosa isolate were treated in vitro with methylene 
blue (MB) and temoporfin under different conditions following exposure to light at 640 nm and in no- light (dark) conditions. Bac-
terial cell viability [colony- forming units (c.f.u.) ml−1] was then calculated. Against P. aeruginosa, when MB was used as the pho-
tosensitizer, no phototoxic effect was observed in either light or dark conditions. After treatment with temoporfin, a reduction 
of less than one log (7.00×107 c.f.u. ml−1) was observed in the light after 20 min of exposure. However, temoporfin completely 
eradicated S. aureus in both light and dark conditions after 1 min (where a seven log reduction in c.f.u. ml−1 was observed). 
Methylene blue resulted in a loss of S. aureus viability, with a two log reduction in bacterial viability (c.f.u. ml−1) reported in both 
light and dark conditions after 20 min exposure time. Temoporfin demonstrated greater antimicrobial efficacy than MB against 
both the S. aureus and P. aeruginosa isolates tested. At 12.5 µM temoporfin resulted in complete eradication of S. aureus. In light 
of this study, further research into the validity of PACT, coupled with the photosensitizers (such as temoporfin), should be con-
ducted in order to potentially develop alternative antimicrobial treatment regimes for burn wounds.
INTRODUCTION
Widespread antibiotic misuse, coupled with an increasingly 
mobile global population, has facilitated an alarming increase 
in the rates of emerging antimicrobial- resistant (AMR) 
bacteria. The treatment of AMR bacteria results in both a 
decline in the physiological and psychological well- being 
of patients (including morbidity and mortality) and serious 
financial burdens to healthcare providers and their respective 
countries worldwide [1]. In Europe alone, multidrug- resistant 
(MDR) bacteria are estimated to be responsible for ~25 000 
deaths per year [2]. Furthermore, it is estimated that by 2050 
mortality rates attributed to AMR bacterial infections will 
surpass 10 million people per annum, superseding cancer 
as the leading cause of global mortality [3, 4]. Commonly 
isolated AMR bacteria from patients include methicillin- 
resistant Staphylococcus aureus (MRSA) [5], vancomycin- 
resistant Enterococcus spp. (VRE) [6], carbapenem- resistant 
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The main therapeutic strategies that are currently used to 
control AMR include antimicrobial stewardship, improved 
infection control and the development of new antimicrobials 
(including novel antibiotics) [9]. However, since the ‘golden 
era’ of antibiotic discovery (~1950–1970) [10], the develop-
ment and approval of novel antibiotic classes has decreased 
significantly. This is mainly due to the high cost (>USD 
$1 billion for new molecular entities) involved in antibiotic 
development, the low success rate and a lengthy process time 
(10–15 years) [11, 12]. In addition, the limited mechanism of 
action of most antibiotics has indicated that resistance is likely 
to develop and therefore novel antibiotics potentially have a 
limited shelf life [9].
Burns patients are at high risk of nosocomial infection due to 
compromised innate host defences (in this instance damage 
to the epidermidis) [13]. Bacterial colonization of burns 
can result in invasive infection, septicaemia, multi- organ 
failure and ultimately death [14]. Pseudomonas aeruginosa 
is the most commonly isolated bacteria from burn wounds, 
followed by S. aureus [15].
The antimicrobial effect of photodynamic antimicrobial 
chemotherapy (PACT) relies on three components: the pres-
ence of oxygen (O2), a photosensitizer and a wavelength of 
light that coincides with the peak absorption of the photosen-
sitizers [16]. Methylene blue (MB) is a well- established photo-
sensitizer that has been extensively documented throughout 
the past decade [17, 18]. Due to the antimicrobial efficacy 
of MB against a broad range of micro- organisms it is often 
utilized as a potent photodynamic therapy (PDT) drug for the 
local treatment of periodontal diseases [19, 20]. The efficiency 
of MB- mediated PACT has also been confirmed on antibiotic- 
resistant polymicrobial biofilms of P. aeruginosa and MRSA 
in a maxillary sinus model [21]. In addition, several in vitro 
studies have assessed its antimicrobial efficacy against a range 
of bacteria commonly isolated from burn infections [22, 23].
Temoporfin is a second- generation photosensitizer that has 
been utilized successfully in PDT to treat squamous cell carci-
noma of the head and neck and has been investigated for use 
as a treatment for other cancers, such as biliary tract carci-
nomas [24, 25]. Temoporfin has been shown to achieve the 
same PDT response at lower concentrations and with lower 
light doses than its first- generation predecessors [26, 27]. In 
addition, temoporfin has a better safety profile than other 
photosensitizers, as it does not cause damage to underlying 
anatomical structures [26, 27]. Therefore, temoporfin has 
potential as a promising photosensitizer, although its anti-
bacterial efficacy has not yet been thoroughly characterized 
in the context of burn infections.
Novel therapies to treat burn infections are urgently needed; 
particularly therapies that will not facilitate the develop-
ment of antimicrobial resistance. One potential avenue to 
be explored is PACT. The current study aimed to assess the 
antimicrobial efficacy of methylene blue- and temoporfin- 
mediated PACT against both Gram- positive and Gram- 
negative bacterial species (namely S. aureus and P. aeruginosa) 
that are commonly isolated from burn infections
METHODS
Bacterial cultures
S. aureus (NCTC 6571) and P. aeruginosa (B9T2436) were 
utilized throughout this study. Both species of bacteria were 
cultured aerobically in Luria–Bertani broth (LB) (Fisher 
Scientific, USA) in a shaking incubator at 180 r.p.m. for 24 h 
at 37 °C. Following incubation, the bacterial cultures were 
normalized in LB broth to achieve an optical density (OD600 
nm) of 0.05 (±0.01), equating to approximately 1.0×10
6 colony- 
forming units (c.f.u.) ml−1.
Photosensitizers and light source
Methylene blue (Sigma Aldrich, UK) was dissolved in sterile 
water to produce a 1 % stock solution (w/v) (10 mg ml−1). 
Temoporfin (Sigma Aldrich, UK) was dissolved in absolute 
ethanol (≥99.8 %; Sigma Aldrich, UK) at a concentration 
of 1 mM and stored at −20 °C prior to use. Both photosen-
sitizers were stored in a dark environment to minimize 
light exposure prior to experimentation. For the MB PACT 
experiments, the concentration of MB used was 1 mg ml−1 
(3.13 mM) and the concentration of temoporfin was 50 µM 
for P. aeruginosa and 12.5 µM for S. aureus. A portable 
light- emitting diode (LED) PDT light source that had a 
red wavelength (λ) (640 nm) was utilized throughout this 
study. Previous studies have determined that the maximum 
absorption for methylene blue and temoporfin is 668 and 
650 nm, respectively [27, 28].
PACT assays
Photodynamic antimicrobial chemotherapy experiments 
were conducted in clear, flat- bottom, 96- well microtitration 
plates (Fisher Scientific, UK). S. aureus and P. aeruginosa 
were exposed to four different parameters in the presence 
of both MB and temoporfin, and red light. A maximal light 
exposure time of 20 min was used, due to the assumption 
that patients would tolerate longer treatment times poorly. 
All PACT experiments were conducted in triplicate alongside 
a LB broth (negative control) (n=3). The bacteria were tested 
in the presence of the light and a photosensitizer (L+P+) 
– methylene blue (1 mg ml−1) or temoporfin (50 µM used 
for P. aeruginosa and 12.5 µM for S. aureus). The bacterial 
suspensions (~1.0×106 c.f.u. ml−1) were incubated in the 
dark for 20 min by covering the sterile microtitre plates with 
aluminium foil. Samples were illuminated using red light 
(λ=640 nm) for up to 20 min. Serial dilutions were performed 
at intervals of 1, 10 and 20 min of light exposure and plated 
onto LB agar plates (Fisher Scientific, USA). The inoculated 
agar was incubated overnight at 37 °C in the dark. After incu-
bation, the bacterial colonies were enumerated and the c.f.u. 
ml−1 determined. The antimicrobial efficacy testing for the 
light and the photosensitizer was also carried out without the 
light and a photosensitizer (L−P−) as a negative control, with 
no light but with a photosensitizer (L−P+) or with light but 
with no photosensitizer (L+P−).
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Statistical analysis
Statistical analysis was conducted by performing two- way 
analysis of variance (ANOVA) coupled with Tukey’s multiple 
comparison tests for post hoc analysis using GraphPad Prism 
(version 8.4.2; GraphPad Software, USA) to determine 
significant differences at a confidence level of 95 % (P<0.05). 
Error bars represent the standard error of the mean. Aster-
isks denote significance, *P≤0.05, **P≤0.01, ***P≤0.001 and 
****P≤0.0001.
RESULTS
The effect of MB- and temoporfin-mediated PDT on 
P. aeruginosa
Initially, the effect of PACT using MB on P. aeruginosa was 
determined. It was demonstrated that the number of viable 
cells increased with increased light exposure in the untreated 
experimental group (L−P−) with a mean of 5.44×107 c.f.u. 
ml−1 at 1 min and 8.00×107 c.f.u. ml−1 by 20 min (Fig. 1). There 
was also a similar pattern observed with the L+P+ and L+P− 
groups. The L−P + group, representing the dark control and 
hence the antimicrobial activity of MB alone, was the only 
group to show a decrease in the number of viable cells with 
increasing time. However, no statistical difference was found 
between the negative control (L−P−) and (L−P+) at 20 min 
(P=0.9434) (Fig. 1).
The effect of temoporfin- mediated PACT on P. aeruginosa was 
determined. In contrast to the MB- mediated PACT experi-
ment with P. aeruginosa, the L+P+ group demonstrated a 
decrease in cell viability from 1.49×108 c.f.u. ml−1 at 1 min 
to 7.00×107 c.f.u. ml−1 by 20 min. The number of bacterial 
colonies present at 20 min was significantly lower than for all 
other experimental groups. The bacterial viability (c.f.u. ml−1) 
in the L−P− group was 2.89×108 c.f.u. ml−1 at 20 min, and the 
antimicrobial effect of temoporfin with 20 min of red light 
exposure resulted in 7.00×107 c.f.u. ml−1 (Fig. 2).
The effect of MB- and temoporfin-mediated PDT on 
S. aureus
The MB- mediated PACT experiments demonstrated that the 
Gram- positive bacterium, S. aureus, was more susceptible to 
MB than the Gram- negative bacterium, P. aeruginosa. Cell 
viability was determined at 2.83×107 c.f.u. ml−1 and 2.05×106 
c.f.u. ml−1 between 1 and 20 min in the L−P + and L+P+ 
groups, respectively (Fig. 3). The viable bacterial counts were 
higher (with statistical significance) in the experimental 
controls compared to the L+P+ and L−P + groups at 1, 10 
and 20 min, indicating that MB demonstrated antimicrobial 
efficacy under both light and dark conditions against S. 
aureus. The toxicity of MB alone when no light was applied 
had a greater effect on S. aureus than when illuminated, with 
the c.f.u. ml−1 being consistently lower at 1, 10 and 20 min in 
the L−P + group when compared to the L+P+ group. Relative 
to the control (L−P−) at 20 min (1.79×107 c.f.u. ml−1), when 
MB was used without exposure to light (L−P+), a reduction 
in viable S. aureus (1.50×105 c.f.u. ml−1) was achieved, whilst 
Fig. 1. Effect of MB (1 mg ml−1) on P. aeruginosa (B9T2436) after 1, 
10 and 20 min of red light exposure (λ=640 nm; n=3). Group L+P+, 
incubated with MB for 20 min, and then irradiated with red light. Group 
L+P−, no incubation with MB but exposed to red light. Group L−P−, no 
incubation with MB or exposure to red light. Group L−P+, incubated with 
MB, but not exposed to red light. Bars represent median value +range 
of three biological replicates. Two- way ANOVA tests were performed 
between experimental groups at different time points. Asterisks denote 
significance (*P≤0.05, **P≤0.01).
Fig. 2. Effect of temoporfin (50 µM) on P. aeruginosa (B9T2436) after 
1, 10 and 20 min of red light exposure (λ=640 nm; n=3). Group L+P+, 
incubated with temoporfin for 20 min, and then exposed to red light. 
Group L+P−, not incubated with temoporfin but exposed to red light. 
Group L−P−, not incubated with temoporfin or exposed to red light. 
Group L−P+), incubated with temoporfin but not exposed to red light. 
Bars represent the mean of three biological replicates whilst error 
bars denote standard error of mean (sem). Two- way ANOVA tests were 
performed between experimental groups at different time points. 
Asterisks denote significance (*P≤0.05).
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the phototoxicity group, L+P+, reported 8.67×105 c.f.u. ml−1 
of viable S. aureus (Fig. 3).
Temoporfin also demonstrated greater antimicrobial efficacy 
against the Gram- positive bacterium, S. aureus (Fig. 4). The 
killing effect of temoporfin at 12.5 µM was substantially greater 
than that of MB (which was tested at a higher concentration of 
3.13 mM), with a complete eradication of S. aureus observed 
in both the L−P + and L+P+ groups after 1 min (Fig. 4). The 
L−P + and L+P+ groups both showed statistically significant 
differences from the L−P− and L+P− groups at 1, 10 and 
20 min. This indicated that temoporfin had an antimicrobial 
effect against S. aureus in the dark at 12.5 µM, with complete 
eradication observed after 1 min of incubation (Fig. 4).
DISCUSSION
This study aimed to determine the efficacy of light- activated 
photosensitizers against bacterial species commonly found 
in burn wound infections. The results from this in vitro study 
demonstrated that S. aureus (a Gram- positive bacterium) 
was more susceptible to killing by the photosensitizers in 
the absence of light than P. aeruginosa (a Gram- negative 
bacterium). Temoporfin demonstrated a photodynamic 
effect against P. aeruginosa and did not demonstrate 
an antimicrobial effect in the absence of light against P. 
aeruginosa. Incubation of S. aureus with temoporfin at 
12.5 µM (but no light exposure) demonstrated antimicro-
bial activity, with complete bacterial eradication after 1 min. 
Temoporfin at 12.5 µM combined with red light exposure 
also resulted in the complete loss of S. aureus viability after 
1 min, and therefore exclusive phototoxicity activity could 
not conclusively be determined. The toxicity of MB when 
tested against S. aureus in the dark was greater than its 
antimicrobial activity following exposure to light. MB did 
not demonstrate an antimicrobial effect in the absence of 
light against P. aeruginosa
The greater sensitivity of Gram- positive bacteria to photo-
sensitizers has been reported by other in vitro studies. In 
2001, Usacheva et al. detailed the photobactericidal effi-
cacy of the photosensitizers, MB and toluidine blue (TB), 
which was assessed against a range of Gram- positive and 
Gram- negative bacteria [20]. It was reported that the 
concentrations of both temoporfin and MB required to 
achieve complete eradication of Gram- negative bacteria 
with light were in general 3- to 30- fold higher than those 
required to kill the Gram- positive bacteria tested. Another 
in vitro study conducted by Yang et al. (2012) reported 
complete eradication of MRSA with temoporfin after a 
90 min incubation period followed by continuous expo-
sure to 100 J cm−2 of light (λ=652 nm) [29]. The discrep-
ancy in sensitivity is believed to be due to differences in 
cell wall structure, with Gram- negative bacteria having 
an additional negatively charged outer membrane that 
impedes the diffusion of non- cationic photosensitizers 
[30]. However, this does not fully explain the decreased 
efficacy of MB, as it is a positively charged photosensi-
tizer. An alternative explanation was provided in a study 
Fig. 3. Effect of MB (1 mg ml−1) on S. aureus c.f.u. ml−1 after 1, 10 and 
20 min of red light exposure (λ=640 nm; n=3). Group L+P+, incubated 
with MB for 20 min, and then exposed to red light. Group L+P−, no 
incubation with MB but exposed to red light. Group L−P−, no exposure 
to MB and no exposure to red light. Group L−P+, incubation with 
MB but no exposure to red light. Bars represent the mean of three 
biological replicates whilst error bars denote standard error of mean 
(sem). Two- way ANOVA tests were performed between experimental 
groups at different time points. Asterisks denote significance (*P≤0.05, 
**P≤0.01 and ***P≤0.001).
Fig. 4. Effect of temoporfin (12.5 µM) on S. aureus c.f.u. ml−1 after 1, 
10 and 20 min of red light exposure (λ=640 nm; n=3). Group L+P+, 
incubated with temoporfin for 20 min, and then exposed to red light. 
Group L+P−, no incubation with temoporfin but exposed to red light. 
Group L−P−, no incubation with temoporfin or exposure to red light. 
Group L−P+, incubated with temoporfin but not exposed to red light. 
Bars represent the mean of three biological replicates whilst error 
bars denote standard error of mean (sem). Two- way ANOVA tests were 
performed between experimental groups at different time points. 
Asterisks denote significance (*P≤0.05, **P≤0.01 and ***P≤0.001).
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by Rineh et al. (2018), which reported a potential efflux 
mechanism against MB [31]. In this study it was shown 
that a NorA efflux pump inhibitor–methylene blue (EPI–
MB) hybrid compound displayed a greater PDT against the 
Gram- negative bacteria Escherichia coli and Acinetobacter 
baumannii than MB alone. The antimicrobial activity 
against Gram- negative bacteria may therefore be enhanced 
by mitigating the effect of efflux pumps, through the use 
of shorter incubation times with photosensitizers, or by 
repeated doses of photosensitizers.
Another potential explanation for the poor photodynamic 
efficacy of MB against P. aeruginosa is a phenomenon 
called the self- shielding effect [30]. This arises when high 
concentrations of the photosensitizer are present in solu-
tion and absorb a significant proportion of the light, thereby 
reducing the light exposure to photosensitizer- loaded cells 
[30]. For many photosensitizers this self- shielding effect is 
observed when the concentration reaches ≥300 µM [30]. 
The concentration of MB used throughout this study was 
3.13 mM and was greater than that of the temoporfin, and 
was selected since studies in this area use a range of MB 
concentrations from ≤25 μg ml−1 to 10 mg ml−1 and hence 
the MB concentration selected for use in this study was 
taken for use at a conservative mid- range [30, 32–34]. The 
use of this higher concentration may explain the potential 
shielding effect demonstrated.
The current study demonstrated that a temoporfin concen-
tration of 50 µM enabled a photodynamic effect to be 
observed against P. aeruginosa. P. aeruginosa cell viability at 
this concentration reduced from 2.89×108 to 7.00×107 c.f.u. 
ml−1. In a previous study by Yang et al. (2012), a similar 
phenomenon was observed; no overall significant reduction 
in P. aeruginosa viability was observed when temoporfin 
was utilized at 12.5 µM, and the authors stated that this was 
likely due to the neutral charge of temoporfin, which meant 
that penetration of the outer membrane was less probable 
[29]. The threshold required by the American Society of 
Microbiology for a treatment to be termed antimicrobial is 
when it can achieve at least a three log reduction in c.f.u. 
ml−1 (killing efficiency of 99.9 %) [35]. It would therefore 
appear to be an ineffective antimicrobial treatment against 
antibiotic- resistant Gram- negative bacteria when used at 
this concentration.
Future research may involve the use of temoporfin as a 
photosensitizer against resistant strains of bacteria, in 
particular MRSA, as this species commonly colonizes 
burn wounds. This research has shown that temoporfin is 
effective in the eradication of a Gram- positive S. aureus 
species, meaning that it may result in the killing of other 
Gram- positive species causing burn infections, such as 
Enterococcus spp. This has been shown by Kranz et al. 
(2011), who described a six log reduction in Enterococcus 
faecalis c.f.u. ml−1 after treatment with 30 µM of a liposomal 
formulation of temoporfin, subjected to a light dose of 100 J 
cm−2, at a wavelength of 652 nm [36].
CONCLUSIONS
Temoporfin demonstrated greater antimicrobial efficacy 
than MB against a S. aureus isolate and a P. aeruginosa 
isolate tested in vitro. At 12.5 µM, temoporfin resulted in 
complete eradication of S. aureus. Although the use of light 
and temoporfin decreased the numbers of P. aeruginosa, 
viable cells were still present following treatment. The 
results of this study demonstrate that the antimicrobial 
activity of temoporfin as a photosensitizer could be more 
suited to Gram- positive bacterial infections. In light of this 
study, further research is warranted for the development of 
an alternative treatment option for burn wound infections.
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